

# M Naveed Shaik

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3766183/publications.pdf>

Version: 2024-02-01

33  
papers

2,102  
citations

361296

20  
h-index

434063

31  
g-index

34  
all docs

34  
docs citations

34  
times ranked

2810  
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. <i>Leukemia</i> , 2019, 33, 379-389.	3.3	396
2	Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 568-576.	3.2	323
3	Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. <i>Blood</i> , 2012, 119, 4597-4607.	0.6	278
4	P-glycoprotein and Breast Cancer Resistance Protein Influence Brain Distribution of Dasatinib. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2009, 330, 956-963.	1.3	181
5	Treatment with PF-04449913, an oral smoothed antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study. <i>Lancet Haematology</i> , 2015, 2, e339-e346.	2.2	102
6	Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. <i>American Journal of Hematology</i> , 2018, 93, 1301-1310.	2.0	98
7	Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS. <i>Clinical Cancer Research</i> , 2018, 24, 2294-2303.	3.2	87
8	P-glycoprotein-Mediated Active Efflux of the Anti-HIV1 Nucleoside Abacavir Limits Cellular Accumulation and Brain Distribution. <i>Drug Metabolism and Disposition</i> , 2007, 35, 2076-2085.	1.7	83
9	Substrate-Dependent Breast Cancer Resistance Protein (Bcrp1/Abcg2)-Mediated Interactions: Consideration of Multiple Binding Sites in in Vitro Assay Design. <i>Drug Metabolism and Disposition</i> , 2009, 37, 560-570.	1.7	69
10	Investigation of the Role of Breast Cancer Resistance Protein (Bcrp/Abcg2) on Pharmacokinetics and Central Nervous System Penetration of Abacavir and Zidovudine in the Mouse. <i>Drug Metabolism and Disposition</i> , 2008, 36, 1476-1484.	1.7	67
11	A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 1044-1051.	3.2	61
12	Interactions of pluronic block copolymers on P-gp efflux activity: Experience with HIV-1 protease inhibitors. <i>Journal of Pharmaceutical Sciences</i> , 2008, 97, 5421-5433.	1.6	51
13	Glasdegib plus intensive/nonintensive chemotherapy in untreated acute myeloid leukemia: BRIGHT AML 1019 Phase III trials. <i>Future Oncology</i> , 2019, 15, 3531-3545.	1.1	38
14	A Phase 2 Randomized Study of Low Dose Ara-C with or without Glasdegib (PF-04449913) in Untreated Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome. <i>Blood</i> , 2016, 128, 99-99.	0.6	36
15	Phase 1 Dose-Escalation Study of PF-04449913, An Oral Hedgehog (Hh) Inhibitor, in Patients with Select Hematologic Malignancies. <i>Blood</i> , 2011, 118, 424-424.	0.6	33
16	Evaluation of the effect of food and ketoconazole on the pharmacokinetics of the smoothed inhibitor PF-04449913 in healthy volunteers. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 411-418.	1.1	31
17	Investigation of the micellar effect of pluronic P85 on P-glycoprotein inhibition: Cell accumulation and equilibrium dialysis studies. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 4170-4190.	1.6	26
18	Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib. <i>Leukemia Research</i> , 2019, 79, 38-44.	0.4	25

#	ARTICLE	IF	CITATIONS
19	Metabolism, excretion and pharmacokinetics of [ <sup>14</sup> C]glasdegib (PF-04449913) in healthy volunteers following oral administration. <i>Xenobiotica</i> , 2017, 47, 1064-1076.	0.5	21
20	Evaluation of the effect of rifampin on the pharmacokinetics of the Smoothened inhibitor glasdegib in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1346-1353.	1.1	20
21	Evaluation of the effects of formulation, food, or a proton-pump inhibitor on the pharmacokinetics of glasdegib (PF-04449913) in healthy volunteers: a randomized phase I study. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 83, 463-472.	1.1	17
22	Population Pharmacokinetics of Glasdegib in Patients With Advanced Hematologic Malignancies and Solid Tumors. <i>Journal of Clinical Pharmacology</i> , 2020, 60, 605-616.	1.0	13
23	Evaluation of the effect of new formulation, food, or a proton pump inhibitor on the relative bioavailability of the smoothened inhibitor glasdegib (PF-04449913) in healthy volunteers. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 1249-1260.	1.1	12
24	Absolute Oral Bioavailability of Glasdegib (PF-04449913), a Smoothened Inhibitor, in Randomized Healthy Volunteers. <i>Clinical Pharmacology in Drug Development</i> , 2019, 8, 895-902.	0.8	8
25	An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 451-459.	1.1	6
26	Population Pharmacokinetic/Pharmacodynamic Evaluation of the Relationship between Glasdegib Treatment/ Exposure and Overall Survival in AML Patients. <i>Blood</i> , 2018, 132, 1450-1450.	0.6	5
27	Pharmacokinetics and Safety of Glasdegib in Participants With Moderate/Severe Hepatic Impairment: A Phase I, Single-Dose, Matched Case-Control Study. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 707-717.	0.8	4
28	Clinical and Model-Based Evaluation of the Effect of Glasdegib on Cardiac Repolarization From a Randomized Thorough QT Study. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 272-282.	0.8	3
29	Evaluation of the Relationship of Glasdegib Exposure and Safety End Points in Patients With Refractory Solid Tumors and Hematologic Malignancies. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 349-359.	1.0	2
30	Exposure-response modeling of the effect of glasdegib on cardiac repolarization in patients with cancer. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 927-935.	1.3	2
31	Evaluation of the impact of renal impairment on the pharmacokinetics of glasdegib in otherwise healthy volunteers. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 241-250.	1.1	2
32	Abstract 3887: Population pharmacokinetic/pharmacodynamic evaluation of the relationship between glasdegib exposure and safety endpoints in cancer patients. , 2019, , .		1
33	Abstract 3889: Population pharmacokinetic/pharmacodynamic evaluation of the effect of glasdegib exposure on cardiac repolarization (QT interval) in cancer patients. , 2019, , .		1